DelveInsight’s “Hypoparathyroidism Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Hypoparathyroidism, historical and forecasted epidemiology as well as the Hypoparathyroidism market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Hypoparathyroidism market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hypoparathyroidism Market Forecast
Some of the key facts of the Hypoparathyroidism Market Report:
-
The Hypoparathyroidism market size was valued approximately USD 360 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
-
In September 2024, Septerna, a clinical-stage biotechnology company leading the way in GPCR-targeted drug discovery, announced the initiation of dosing for the first participants in its Phase 1 clinical trial of SEP-786. This novel, potent, and selective oral small molecule parathyroid hormone 1 receptor (PTH1R) agonist is being developed to treat hypoparathyroidism. The Phase 1 trial, which includes both single-ascending dose (SAD) and multiple-ascending dose (MAD) cohorts, aims to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SEP-786 in healthy adult volunteers.
-
In May 2024, Amolyt Pharma has reported that the FDA has awarded fast track designation to eneboparatide, a drug developed for the treatment of hypoparathyroidism. This medication, currently undergoing assessment in the Phase III Calypso clinical trial, has demonstrated promise in previous studies by enhancing critical calcium levels and bone health. Results from the Phase III trial are anticipated to be disclosed next year, with the specific date yet to be determined.
-
In May 2024, Ascendis Pharma A/S (Nasdaq: ASND) has disclosed findings from a post-hoc analysis of the Phase 3 PaTHway Trial, showcasing significant and enduring enhancements in renal function among adults with chronic hypoparathyroidism treated with TransCon PTH (palopegteriparatide).
-
The overall population with hypoparathyroidism in the 7MM was approximately 284,000 in 2022 and is anticipated to rise by the year 2034.
-
Around 22,500 individuals were affected by Hypoparathyroidism in Japan in 2022. Forecasts indicate an expected rise in these cases from 2024 to 2034.
-
In the EU4 and the UK, the United Kingdom had the highest prevalence of hypoparathyroidism in 2022, with approximately 35,000 cases, surpassing Germany and France. In contrast, Spain recorded the lowest prevalent population of hypoparathyroidism.
-
Upcoming therapies for hypoparathyroidism that show significant promise include TransCon PTH by Ascendis Pharma, EB612 (PTH 1-34), and Encaleret by Bridgebio/Calcilytix Therapeutics.
-
Key Hypoparathyroidism Companies: Ascendis Pharma, EnteraBio, Bridgebio/Calcil ytix Therapeutics, Shire, and others
-
Key Hypoparathyroidism Therapies: TransCon PTH, Encaleret, rhPTH(1-84), EB612 (EBP05), NPSP558, and others
-
The Hypoparathyroidism epidemiology based on gender analyzed that Hypoparathyroidism affects females more than males.
-
The Hypoparathyroidism market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hypoparathyroidism pipeline products will significantly revolutionize the Hypoparathyroidism market dynamics.
Hypoparathyroidism Overview
Hypoparathyroidism is a rare endocrine disorder characterized by insufficient levels of parathyroid hormone (PTH) in the body. PTH is produced by the parathyroid glands, which are located in the neck and are responsible for regulating calcium and phosphorus levels in the blood.
Get a Free sample for the Hypoparathyroidism Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/hypoparathyroidism-market
Hypoparathyroidism Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Hypoparathyroidism Epidemiology Segmentation:
The Hypoparathyroidism market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Total Prevalence of Hypoparathyroidism
-
Prevalent Cases of Hypoparathyroidism by severity
-
Gender-specific Prevalence of Hypoparathyroidism
-
Diagnosed Cases of Episodic and Chronic Hypoparathyroidism
Download the report to understand which factors are driving Hypoparathyroidism epidemiology trends @ Hypoparathyroidism Epidemiology Forecast
Hypoparathyroidism Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hypoparathyroidism market or expected to get launched during the study period. The analysis covers Hypoparathyroidism market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Hypoparathyroidism Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Hypoparathyroidism Therapies and Key Companies
- TransCon PTH: Ascendis Pharma
-
Encaleret: Bridgebio/Calcil ytix Therapeutics
-
rhPTH(1-84): Shire
-
EB612 (EBP05): Entera Bio Ltd.
-
NPSP558: Shire
Discover more about therapies set to grab major Hypoparathyroidism market share @ Hypoparathyroidism Treatment Landscape
Hypoparathyroidism Market Strengths
-
Based on the route of administration, the parenteral method will remain the fastest-growing segment compared to oral methods.
-
Extensive cancer radiation treatment on the neck or face and new technology advancements for the treatment of hypoparathyroidism is set to further enhance the overall development of the hypoparathyroidism treatment market
Hypoparathyroidism Market Opportunities
-
In terms of drug class, calcium supplements might remain the most preferred in the coming future, with around 38% market share. PTH will also showcase a substantial growth rate.
-
Sales of hypoparathyroidism treatment drugs through retail pharmacies will generate maximum revenue, followed by hospital pharmacies.
Scope of the Hypoparathyroidism Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Hypoparathyroidism Companies: Ascendis Pharma, EnteraBio, Bridgebio/Calcil ytix Therapeutics, Shire, and others
-
Key Hypoparathyroidism Therapies: TransCon PTH, Encaleret, rhPTH(1-84), EB612 (EBP05), NPSP558, and others
-
Hypoparathyroidism Therapeutic Assessment: Hypoparathyroidism current marketed and Hypoparathyroidism emerging therapies
-
Hypoparathyroidism Market Dynamics: Hypoparathyroidism market drivers and Hypoparathyroidism market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Hypoparathyroidism Unmet Needs, KOL’s views, Analyst’s views, Hypoparathyroidism Market Access and Reimbursement
To know more about Hypoparathyroidism companies working in the treatment market, visit @ Hypoparathyroidism Clinical Trials and Therapeutic Assessment
Table of Contents
1. Hypoparathyroidism Market Report Introduction
2. Executive Summary for Hypoparathyroidism
3. SWOT analysis of Hypoparathyroidism
4. Hypoparathyroidism Patient Share (%) Overview at a Glance
5. Hypoparathyroidism Market Overview at a Glance
6. Hypoparathyroidism Disease Background and Overview
7. Hypoparathyroidism Epidemiology and Patient Population
8. Country-Specific Patient Population of Hypoparathyroidism
9. Hypoparathyroidism Current Treatment and Medical Practices
10. Hypoparathyroidism Unmet Needs
11. Hypoparathyroidism Emerging Therapies
12. Hypoparathyroidism Market Outlook
13. Country-Wise Hypoparathyroidism Market Analysis (2020–2034)
14. Hypoparathyroidism Market Access and Reimbursement of Therapies
15. Hypoparathyroidism Market Drivers
16. Hypoparathyroidism Market Barriers
17. Hypoparathyroidism Appendix
18. Hypoparathyroidism Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
